文献

J-GLOBAL ID：202202247836620751   整理番号：22A1074279

複数タイプのがんで免疫チェックポイント阻害の有効性の予測を改善する

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

著者 (65件)： CHOWELL Diego (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  YOO Seong-Keun (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  VALERO Cristina (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  PASTORE Alessandro (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  LEE Mark (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  HOEN Douglas (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  PATEL Neal (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MAKAROV Vladimir (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MA Xiaoxiao (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  VUONG Lynda (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  SABIO Erich Y. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  WEISS Kate (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  KUO Fengshen (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  RIAZ Nadeem (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  BALACHANDRAN Vinod P. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  HAKIMI A. Ari (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  ABDEL-WAHAB Omar (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MORRIS Luc G. T. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  CHAN Timothy A. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  CHOWELL Diego (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  YOO Seong-Keun (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  VALERO Cristina (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  LEE Mark (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  HOEN Douglas (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  PATEL Neal (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MAKAROV Vladimir (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MA Xiaoxiao (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  WEISS Kate (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  KUO Fengshen (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  RIAZ Nadeem (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  HAKIMI A. Ari (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MORRIS Luc G. T. (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  WEINHOLD Nils (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  CHAN Timothy A. (Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  CHOWELL Diego (Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA) ,  YOO Seong-Keun (Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA) ,  HOEN Douglas (Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA) ,  MAKAROV Vladimir (Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA) ,  MA Xiaoxiao (Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA) ,  CHAN Timothy A. (Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA) ,  VALERO Cristina (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  PATEL Neal (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  ADUSUMILLI Prasad S. (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  BALACHANDRAN Vinod P. (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  PLITAS George (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  HAKIMI A. Ari (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MORRIS Luc G. T. (Dep. of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  KRISHNA Chirag (Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  SHI Hongyu (Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  SHI Hongyu (Dep. of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  GOENEN Mithat (Dep. of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  KELLY Daniel W. (Information Systems, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  LENZ Tobias L. (Res. Unit for Evolutionary Immunogenomics, Dep. of Biology, Univ. Hamburg, Hamburg, DEU) ,  SAMSTEIN Robert M. (Precision Immunology Inst., Icahn School of Medicine at Mount Sinai, New York, NY, USA) ,  RIAZ Nadeem (Dep. of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  WEINHOLD Nils (Dep. of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  CHAN Timothy A. (Dep. of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  SHOUSHTARI Alexander N. (Dep. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  POSTOW Michael A. (Dep. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  MOTZER Robert J. (Dep. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  LADANYI Marc (Dep. of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  ZEHIR Ahmet (Dep. of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  BERGER Michael F. (Dep. of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA) ,  CHAN Timothy A. (Weill Cornell School of Medicine, New York, NY, USA) ,  CHOWELL Diego (Dep. of Oncological Sci., Precision Immunology Inst., Tisch Cancer Inst., Icahn School of Medicine at Mount Sinai, New York, NY, USA)
資料名： Nature Biotechnology  (Nature Biotechnology)
巻： 40  号： 4  ページ： 499-506  発行年： 2022年04月 
JST資料番号： H0870A  ISSN： 1087-0156  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 免疫チェックポイント阻害(ICB)療法に応答するがん患者はごく一部にとどまるが,現在の意思決定の手順は正確さに限界がある。本研究では,ICB療法を受けた異なる16タイプのがんの患者1479人の包括的にキュレーションされたコホート(MSK-IMPACT)から得たゲノムデータ,分子データ,人口統計学的データ,臨床データを統合することにより,ICB応答を予測する機械学習モデルを開発した。このモデルは,後ろ向き解析において,免疫療法に対する臨床応答の予測に関して高い感度と特異性を実現し,各タイプのがんの試験データで全生存期間と無増悪生存期間の両方を予測した。我々のモデルは,米国食品医薬品局から同じ目的で最近承認された腫瘍変異量に基づく予測よりも大幅に優れていた。また,このモデルは,予測に関して最も重要なモデルの特徴の定量評価を可能とする。この方法は,免疫療法に関する臨床的意思決定を大きく改善し,将来の介入に有用な情報をもたらすことが期待される。Copyright Nature Japan KK 2022

シソーラス用語： 意思決定 ,  腫瘍 ,  米国食品医薬品局 ,  ゲノム ,  免疫療法 ,  *治療法 ,  母集団 ,  有効性 ,  機械学習
準シソーラス用語： 人口統計学 ,  臨床データ ,  癌患者 ,  特異性 ,  定量的評価 ,  無増悪生存期間 , 【Automatic Indexing@JST】

分類 (2件)： 腫ようの実験的治療  (GE02040Y) ,  免疫療法薬・血液製剤の基礎研究  (GW22010D)

タイトルに関連する用語 (6件)： タイプ ,  がん ,  免疫 ,  チェックポイント ,  阻害 ,  予測